The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately ...

Surgery to treat chronic sinus disease can be more effective than antibiotics, according to a major clinical trial. The common symptoms of Chronic rhinosinusitis (CRS), or sinusitis, include a blocked ...

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations; FDA ...

This story first appeared in the April 2024 edition of Healthy You, a quarterly health publication and Gazette special section. While spring can be a torturous few months for seasonal allergy ...

After a year of treatment with ETI, chronic rhinosinusitis was improved as measured by the Lund-Mackay sinus CT scoring system (decreasing from 5.8 [IQR 5.0-7.0] to 3.3 points [IQR 2.6-4.2]) and the ...

Even after nasal polyps are removed, they can continue to cause complications. Here’s how to treat some common problems that can arise. Treating nasal polyps isn’t a one-and-done procedure. The ...

Persistent bad breath could signal serious health issues, including heart disease, according to interventional cardiologist Dr. Pradip Jamnadas. His research highlights how poor oral hygiene and ...

DANVILLE, Pa. – Geisinger researchers have discovered a link between chronic sinus disease and bronchiectasis, a chronic and progressive lung disease. The findings, published in the Journal of Allergy ...

(MENAFN- IANS) New Delhi, Aug 30 (IANS) Surgery to treat chronic sinus disease can be more effective than antibiotics, according to a major clinical trial. The common symptoms of Chronic ...